About Us

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.

To date, MPP has signed agreements with twelve patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a long-acting technology, two experimental oral antiviral treatments for COVID-19 and a COVID-19 serological antibody diagnostic test. In 2020, MPP’s mandate was temporarily expanded to include COVID-19 treatments. In 2021 it was expanded further to include the licensing of technology with an initial focus on COVID-19 vaccines and pandemic preparedness.

MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government and SDC.

Featured

VaxPaL

08 June 2021

MPP in Numbers

0

patent holders with MPP signed agreements

0

generic manufactures and product developers have sublicenses from MPP

0 Bn
doses of treatment supplied (Jan 2012 - Dec 2020)
US$0 Mn
dollars saved through MPP'S licences (Jan 2012 - Dec 2020)
By 2030
US$0 Bn
projected dollars saved
0
countries have benefited from access to MPP-licence products
0 Mn
patient-years of treatment through MPPs generic partners (Jan 2012 - Dec 2020)
0
deaths averted (Jan 2012 - Dec 2020)
By 2030
0
deaths averted

For Everyone Everywhere

Discover where we helped and what we have achieved

 

Patent and licensing status: last updated on 11 May 2021. Disclaimer | Product availability data from MPP sublicensees: last updated in October 2021 (data as of 30 June 2021) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Impact Stories

Key Publications

Contact Us

MPP Logo

Subscribe to our Newsletter

Founded & funded by

Unitaid Logo

Other funders